Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Trexquant Investment LP

Trexquant Investment LP lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 51.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,024 shares of the biopharmaceutical company’s stock after selling 46,719 shares during the quarter. Trexquant Investment LP’s holdings in Alnylam Pharmaceuticals were worth $10,359,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ALNY. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $1,045,822,000. Norges Bank acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $577,941,000. Raymond James Financial Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $65,295,000. Jennison Associates LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $61,160,000. Finally, Proficio Capital Partners LLC boosted its position in Alnylam Pharmaceuticals by 25,929.6% during the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock valued at $45,570,000 after purchasing an additional 192,916 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In related news, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,234 shares of company stock valued at $19,958,097. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 4.3 %

Shares of Alnylam Pharmaceuticals stock opened at $266.83 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market capitalization of $34.71 billion, a PE ratio of -122.96 and a beta of 0.30. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock’s fifty day moving average is $260.16 and its 200-day moving average is $260.56.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of recent research reports. Scotiabank raised their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a “sector outperform” rating in a research note on Monday. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a research note on Friday, March 21st. Sanford C. Bernstein dropped their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $316.25.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.